| Literature DB >> 30873220 |
Xueli Cai1, Lili Xia2, Yuesong Pan3, Dian He4, Huiping Zhu4, Tiemin Wei1, Yan He4.
Abstract
BACKGROUND: The prevalence of diabetes and prediabetes were estimated to be 10.9% and 35.7% in the Chinese adult population, respectively, and the middle-aged and elderly Chinese are at even higher risk of diabetes and prediabetes than younger population. With the increasing trend of aging in China, the burden of diabetes and related complications will be aggravated.Entities:
Keywords: Adipose tissue insulin resistance; Peripheral tissue insulin resistance; Prediabetes; Type 2 diabetes; β-Cell function
Year: 2019 PMID: 30873220 PMCID: PMC6402147 DOI: 10.1186/s13098-019-0418-x
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
General characteristics of study population by glucose tolerance
| Variables | NGT | Prediabetes | T2DM |
|
|
|---|---|---|---|---|---|
| Age (years) | 59.4 ± 6.6 | 60.4 ± 7.4 | 62.7 ± 6.1a, b | 0.001 | < 0.001 |
| BMI (kg/m2) | 22.2 ± 2.8 | 23.4 ± 2.9a | 23.7 ± 2.9a | < 0.001 | < 0.001 |
| WHR | 0.89 ± 0.06 | 0.92 ± 0.10a | 0.93 ± 0.06a | < 0.001 | < 0.001 |
| Female (n, %) | 143 (54.4) | 78 (48.4) | 52 (61.2) | 0.154 | 0.153 |
| Education (n, %) | 0.135 | 0.124 | |||
| Primary school and below | 157 (59.7) | 91 (56.5) | 62 (71.9) | ||
| Middle school | 76 (28.9) | 53 (32.9) | 17 (20.0) | ||
| High school and above | 30 (11.4) | 17 (10.6) | 6 (7.1) | ||
| Smoking status (n, %) | 0.163 | 0.158 | |||
| Non-smoker | 165 (62.7) | 93 (57.8) | 55 (64.7) | ||
| Ever-smoker | 28 (10.7) | 29 (18.0) | 1 (16.5) | ||
| Current-smoker | 70 (26.6) | 39 (24.2) | 16 (18.8) | ||
| Drinking status (n, %) | 0.029 | 0.026 | |||
| Non-drinker | 118 (44.9) | 66 (41.0) | 49 (57.7) | ||
| Ever-drinker | 17 (6.4) | 4 (2.5) | 4 (4.7) | ||
| Current-drinker | 128 (48.7) | 91 (56.5) | 32 (37.6) | ||
| LDL-C (mmol/L) | 2.50 ± 0.67 | 2.73 ± 0.72a | 2.64 ± 0.76 | 0.003 | 0.015 |
| HDL-C (mmol/L) | 1.34 ± 0.32 | 1.31 ± 0.33 | 1.34 ± 0.38 | 0.740 | 0.785 |
| TG (mmol/L) | 1.42 ± 0.90 | 1.78 ± 1.14a | 2.01 ± 1.50a | < 0.001 | < 0.001 |
| TC (mmol/L) | 4.77 ± 0.85 | 5.14 ± 0.94a | 5.20 ± 1.00a | < 0.001 | < 0.001 |
| HbA1c (%) | 5.52 ± 0.34 | 5.65 ± 0.32 | 6.72 ± 0.71a, b | < 0.001 | < 0.001 |
| FPG (mmol/L) | 5.24 ± 0.37 | 5.55 ± 0.49 | 7.43 ± 0.57a, b | < 0.001 | < 0.001 |
| 2 h-PG (mmol/L) | 6.26 ± 1.05 | 8.90 ± 1.20a | 13.92 ± 1.38a, b | < 0.001 | < 0.001 |
| SBP (mmHg) | 120.6 ± 15.8 | 127.2 ± 13.2a | 130.7 ± 16.2a | < 0.001 | < 0.001 |
| DBP (mmHg) | 71.1 ± 9.2 | 74.5 ± 7.9a | 75.4 ± 8.4a | < 0.001 | < 0.001 |
| Adipo-IR | |||||
| Q1 (≤ 1.52) | 92 (35.0) | 23 (14.3) | 11 (12.9) | < 0.001 | < 0.001 |
| Q2 (1.53–2.37) | 68 (25.9) | 40 (24.8) | 13 (15.3) | ||
| Q3 (2.38–3.70) | 68 (25.9) | 42 (26.1) | 20 (23.5) | ||
| Q4 (≥ 3.71) | 35 (13.3) | 56 (34.8) | 41 (48.2) | ||
| HOMA-IR | |||||
| Q1 (≤ 0.87) | 82 (31.2) | 28 (17.4) | 11 (12.9) | < 0.001 | < 0.001 |
| Q2 (0.88–1.29) | 76 (28.9) | 38 (23.6) | 8 (9.4) | ||
| Q3 (1.30–1.91) | 66 (25.1) | 45 (28.0) | 23 (27.1) | ||
| Q4 (≥ 1.92) | 39 (14.8) | 50 (31.0) | 43 (50.6) | ||
| HOMA-β | |||||
| Q1 (≤ 40.12) | 59 (22.4) | 36 (22.3) | 43 (50.6) | < 0.001 | 0.135 |
| Q2 (40.13–56.04) | 76 (28.9) | 33 (20.5) | 17 (20.0) | ||
| Q3 (56.05–80.23) | 69 (26.3) | 45 (28.0) | 10 (11.8) | ||
| Q4 (≥ 80.24) | 59 (22.4) | 47 (29.2) | 15 (17.6) | ||
| Fasting CPRI | |||||
| Q1 (≤ 1.16) | 70 (26.6) | 30 (18.6) | 28 (32.9) | 0.005 | 0.005 |
| Q2 (1.17–1.48) | 77 (29.3) | 32 (19.9) | 25 (29.4) | ||
| Q3 (1.49–1.92) | 62 (23.6) | 48 (29.8) | 14 (16.5) | ||
| Q4 (≥ 1.93) | 54 (20.5) | 51 (31.7) | 18 (21.2) | ||
| Postprandial CPRI | |||||
| Q1 (≤ 4.41) | 54 (20.5) | 31 (19.3) | 36 (42.4) | < 0.001 | < 0.001 |
| Q2 (4.42–5.53) | 62 (23.6) | 48 (29.8) | 10 (11.8) | ||
| Q3 (5.54–7.08) | 69 (26.2) | 44 (27.3) | 7 (8.3) | ||
| Q4 (≥ 7.09) | 78 (29.7) | 38 (23.6) | 3 (3.5) | ||
Data are expressed as mean ± SD or number (percentage). P: from analysis of variance; Ptrend: from test for linearity. Differences among three glucose tolerance groups were analyzed by Bonferroni-Dunn post hoc test
aStatistically significant vs. NGT
bStatistically significant vs. prediabetes
Association of indices of insulin resistance and β-cell function to glucose tolerance status
| Variables | Prediabetes vs. NGT | T2DM vs. prediabetes | ||
|---|---|---|---|---|
| Crude OR (95% CI) | Adjusted OR (95% CI) | Crude OR (95% CI) | Adjusted OR (95% CI) | |
| Adipo-IR | ||||
| Q1 (≤ 1.52) | Ref. | Ref. | Ref. | Ref. |
| Q2 (1.53–2.37) |
|
| 0.68 (0.26–1.76) | 0.71 (0.21–2.38) |
| Q3 (2.38–3.70) |
|
| 1.00 (0.41–2.44) | 0.84 (0.26–2.78) |
| Q4 (≥ 3.71) |
|
| 1.53 (0.67–3.49) | 1.74 (0.51–5.96) |
| HOMA-IR | ||||
| Q1 (≤ 0.87) | Ref. | Ref. | Ref. | Ref. |
| Q2 (0.88–1.29) | 1.46 (0.82–2.61) | 1.31 (0.68–2.50) | 0.54 (0.19–1.51) | 0.32 (0.09–1.09) |
| Q3 (1.30–1.91) |
| 1.77 (0.87–3.60) | 1.30 (0.55–3.07) | 0.85 (0.28–2.61) |
| Q4 (≥ 1.92) |
|
| 2.19 (0.98–4.91) | 0.74 (0.22–2.46) |
| HOMA-β | ||||
| Q1 (≤ 40.12) | Ref. | Ref. | Ref. | Ref. |
| Q2 (40.13–56.04) | 0.71 (0.40–1.27) | 0.62 (0.33–1.19) |
| 0.45 (0.17–1.22) |
| Q3 (56.05–80.23) | 1.07 (0.61–1.87) | 0.90 (0.46–1.76) |
|
|
| Q4 (≥ 80.24) | 1.31 (0.74–2.30) | 0.87 (0.41–1.86) |
|
|
| Fasting CPRI | ||||
| Q1 (≤ 1.16) | Ref. | Ref. | Ref. | Ref. |
| Q2 (1.17–1.48) | 0.97 (0.54–1.76) | 0.73 (0.39–1.38) | 0.84 (0.40–1.74) | 1.00 (0.38–2.64) |
| Q3 (1.49–1.92) |
| 1.25 (0.65–2.41) |
|
|
| Q4 (≥ 1.93) |
| 1.27 (0.61–2.66) |
|
|
| Postprandial CPRI | ||||
| Q1 (≤ 4.41) | Ref. | Ref. | Ref. | Ref. |
| Q2 (4.42–5.53) | 1.35 (0.76–2.41) | 1.14 (0.60–2.13) |
|
|
| Q3 (5.54–7.08) | 1.11 (0.62–1.99) | 0.78 (0.41–1.48) |
|
|
| Q4 (≥ 7.09) | 0.85 (0.47–1.53) | 0.55 (0.28–1.07) |
|
|
P and OR: from multivariate logistic regression analysis. The adjusted model included sex, age, BMI, drinking status, LDL-C and HbA1c
Statistically significance values are in italics (p < 0.05)